Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure

Part of paid clinical trials in Milwaukee, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT07274527
Status
Recruiting

Conditions

  • Amnioinfusion
  • CPAP
  • Cord Blood
  • Maternal Morbidity
  • Mechanical Ventilation
  • Meconium
  • NICU Admission
  • Neonatal Acidosis
  • Neonatal Brain Injury
  • Neonatal Respiratory Distress Related Conditions
  • Perinatal Death
  • Perinatal Morbidity
  • Surfactant

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Intrauterine pressure catheter — DEVICE
    Standardized warm amnioinfusion consisting of a 500 mL bolus of warmed (37°C) lactated ringer's infused over 30 minutes through an intrauterine pressure catheter (IUPC), followed by a continuous maintenance infusion of 125 mL/hour until the amniotic fluid clears or delivery.
  • Standard obstetric care at discretion of delivery provider — OTHER
    Route obstetric care at discretion of delivery provider

Study Details

Thick meconium in the amniotic fluid occurs in about one out of seven pregnancies and increases the chance that a newborn may have breathing problems after birth. These problems can include the need for oxygen, breathing support, admission to the neonatal intensive care unit (NICU), or, in severe cases, meconium aspiration syndrome or persistent pulmonary hypertension. Although amnioinfusion or placing sterile fluid into the uterus during labor was previously studied as a way to reduce these complications, earlier research had major limitations. Past studies included all types of meconium, used different fluid types and temperatures, had inconsistent protocols, and did not measure biomarkers of inflammation or look at long-term outcomes. As a result, it is still unclear whether a modern, standardized approach to amnioinfusion can meaningfully improve newborn health when the meconium is truly thick. The PEARL Trial is a randomized clinical trial designed to answer this question. The study will enroll pregnant individuals at or beyond 36 weeks of gestation who develop thick meconium-stained amniotic fluid, confirmed using a simple, objective measurement ("meconium-crit"). Participants will be randomly assigned to receive either: Warm lactated Ringer's (LR) amnioinfusion through an intrauterine pressure catheter (IUPC), following a standardized protocol, or standard care without amnioinfusion. The main goal is to determine whether warm LR amnioinfusion reduces short-term breathing problems in newborns. The study also collects umbilical cord blood at birth to evaluate markers of inflammation and potential brain injury, which may help explain why some infants develop complications. Families will also be contacted when their child is 12 months old to complete a developmental questionnaire that is widely used in pediatric practice. By using a clear definition of thick meconium, a warm LR infusion protocol, fidelity checklists, and long-term follow-up, this trial aims to provide high-quality evidence to guide care in labor and delivery units nationwide.

Key Dates

Start date
May 15, 2026
Status verified
May 2026
Primary completion
Apr 15, 2029
Completion
Apr 15, 2030

Study Design

Enrollment
320 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Warm Lactated Ringer Amnioinfusion
    Standardized warm amnioinfusion consisting of a 500 mL bolus of warmed (37°C) lactated ringer's infused over 30 minutes through an intrauterine pressure catheter (IUPC), followed by a continuous maintenance infusion of 125 mL/hour until the amniotic fluid clears or delivery. Re-administration is permitted if thick meconium persists or the deepest amniotic fluid pocket is \<2 cm by ultrasound.
  • Placebo Comparator: Standard of Care
    Standard obstetric care will be at the discretion of the delivery provider.

Primary Outcome Measure

Number of participants with composite neonatal respiratory morbidity [ Time Frame: 72 hours after delivery ]

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert Hospital and Medical College of Wisconsin Birth CenterMilwaukeeWisconsin53045
Polnaszek Assistant Professor and Principal Investigator, MD MPH
414-805-6600

Find similar trials in Milwaukee, WI

Related Studies